Literature DB >> 26897314

Biologic resurfacing arthroplasty with acellular human dermal allograft and platelet-rich plasma (PRP) in young patients with glenohumeral arthritis-average of 60 months of at mid-term follow-up.

Eddie Y Lo1, Brody A Flanagin2, Wayne Z Burkhead3.   

Abstract

BACKGROUND: The treatment of young patients with glenohumeral arthritis has been challenging. Alternative treatment options include activity modification, arthroscopic débridement, and arthroplasty. Addressing the glenoid during arthroplasty in this population of patients continues to be a significant challenge. In this study, we evaluated the midterm outcomes of hemiarthroplasty with biologic resurfacing of the glenoid with human dermal matrix allograft.
METHODS: Between 2004 and 2011, 55 patients underwent hemiarthroplasty and biologic resurfacing of the glenoid with human dermal matrix allograft. The average age was 50 ± 9 years. Subjective evaluation was performed with the Western Ontario Osteoarthritis of the Shoulder Index, American Shoulder and Elbow Surgeons score, visual analog scale, and Single Assessment Numeric Evaluation. Patients returned to the clinic for clinical examination and radiographic evaluation. The average follow-up was 60 months.
RESULTS: The average postoperative American Shoulder and Elbow Surgeons score was 76 ± 22, and the Western Ontario Osteoarthritis of the Shoulder Index score was 76% ± 22%. The visual analog scale score was 2.4 ± 2.6. The average preoperative Single Assessment Numeric Evaluation score was 33% ± 22%, which significantly improved to 72% ± 22% postoperatively. Eighty-one percent of the patients were satisfied (10/47) or highly satisfied (28/47) with their result. With radiographic evaluation, the average joint space was 1 ± 1 mm preoperatively and 2 ± 1 mm postoperatively. A total of 5 cases (9.1%) were revised to anatomic total shoulder arthroplasty with implantation of a glenoid component. DISCUSSION: Hemiarthroplasty with biologic resurfacing of the glenoid using human dermal matrix allograft can lead to successful midterm outcomes with satisfactory complication and revision rates. Both patient satisfaction and clinical outcome remain high regardless of radiographic outcome.
Copyright © 2016 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glenohumeral arthritis; biologic resurfacing; human dermal matrix allograft; platelet rich plasma; shoulder arthroplasty; young patients

Mesh:

Year:  2016        PMID: 26897314     DOI: 10.1016/j.jse.2015.11.063

Source DB:  PubMed          Journal:  J Shoulder Elbow Surg        ISSN: 1058-2746            Impact factor:   3.019


  4 in total

1.  Arthroscopic Removal of a Loose Polyethylene Glenoid Component With Bone Grafting and Patch Augmentation for Glenoid Osseous Defect.

Authors:  Jeffrey T Abildgaard; Jared C Bentley; Richard J Hawkins; John M Tokish
Journal:  Arthrosc Tech       Date:  2017-05-01

2.  [Interpretation of 2020 American Academy of Orthopaedic Surgeons (AAOS) on the Management of Glenohumeral Joint Osteoarthritis Evidence-Based Clinical Practice Guideline].

Authors:  Xianxiang Xiang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2021-11-15

Review 3.  Soft tissue resurfacing for glenohumeral arthritis: a systematic review.

Authors:  Joshua J Meaike; Diana C Patterson; Shawn G Anthony; Bradford O Parsons; Paul J Cagle
Journal:  Shoulder Elbow       Date:  2019-05-31

4.  Glenohumeral Osteoarthritis: The Role for Orthobiologic Therapies: Platelet-Rich Plasma and Cell Therapies.

Authors:  Luciano A Rossi; Nicolás S Piuzzi; Shane A Shapiro
Journal:  JBJS Rev       Date:  2020-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.